Pharmaceuticals

Sirnaomics Announces 2022 Annual Results

Significant Progress in Clinical Trials for Core Products Reinforces Leading Position in RNA Therapeutics with Strong Product Pipeline Matrix Business Highlights * Clinical development * STP705 -  The part-one Phase IIb interim data on STP705 for the treatment of isSCC was announced, with th...

2023-03-28 19:26 8522

Seegene declares to share Syndromic PCR technologies to prevent future pandemics

* Localization of Seegene Syndromic PCR technologies with global partners for versatile and proactive response to local emerging healthcare demands. * Formation of a collaborative global network to aggressively develop innovative syndromic PCR assays, challenging boundaries of PCR application....

2023-03-28 19:00 2903

Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours

First-in-Class ERAP1 Inhibitor Enters Clinical Development Study to Evaluate GRWD5769 as Monotherapy, as well as in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) OXFORD, UK and MELBOURNE, AUSTRALIA, March 28, 2023 /PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on...

2023-03-28 19:00 2299

OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab

SHENZHEN, China, March 28, 2023 /PRNewswire/ -- OncoVent Co., Ltd. ("OncoVent"), a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company"), yesterday entered into a license agreement with Orient EuroPharma Co., Ltd. ("OEP"). According to the terms of th...

2023-03-28 15:36 2373

BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research

SINGAPORE, March 28, 2023 /PRNewswire/ -- Becton Dickinson Holdings Pte Ltd (BD), a global leader in life science technologies, and the Agency for Science, Technology and Research (A*STAR),Singapore's lead public sector R&D agency, have announced an extended research partnership that will focus o...

2023-03-28 14:12 2912

Tavneos® (avacopan) included in updated EULAR recommendations for the management of AAV

Tavneos® newly introduced in the 2022 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV) Recommendations recognize Tavneos®' ability to induce and sustain remission, lower glucocorticoids-induced toxic effects and pot...

2023-03-28 13:00 3304

Acepodia to Present Preclinical Data of Gamma Delta T cell Therapy Candidate, ACE2016, an off-the-shelf EGFR-targeting γδ2 T cell therapy against EGFR-expressing solid tumors

ALAMEDA, Calif. and TAIPEI, March 27, 2023 /PRNewswire/ -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique antibody-cell conjugation (ACC) technology to address gaps in cancer care, today announced the upcoming poster presentation of new ...

2023-03-28 10:00 2258

HaemaLogiX to present final data from anti-KMA CAR-T preclinical studies at AACR

SYDNEY, March 28, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech company developing novel immunotherapies for multiple myeloma, today announced that its anti-KMA CAR-T cell preclinical development has been completed and is the subject of an abstract accepted for poster presentation...

2023-03-28 09:43 2891

BJ Bioscience Announces Clinical Collaboration with MSD to Evaluate BJ-001 in Combination with KEYTRUDA® (pembrolizumab)

SHANGHAI, March 27, 2023 /PRNewswire/ -- BJ Bioscience, Inc. BJ Bioscience, a biotech company focusing on discovery and development of novel biologics for cancer immunotherapy, today announced that it entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc.,Rah...

2023-03-28 09:19 2667

BioDuro-Sundia Announces Formation of Scientific Advisory Board

IRVINE, Calif., March 28, 2023 /PRNewswire/ -- BioDuro-Sundia, a leading drug discovery, development and commercial services organization backed by Advent International, announced today the establishment of a Discovery Research Scientific Advisory Board (SAB) with the appointment of Andrew Thomas...

2023-03-28 08:30 4429

Boan Biotech Announces 2022 Financial Results

Showing accelerated innovation and strong 225% revenue growth YANTAI, China, March 27, 2023 /PRNewswire/ -- Boan Biotech (6955.HK) today announced its 2022 financial results and recent business developments. 2022 business highlights * Record high in revenue: In 2022, Boan Biotech's revenue was...

2023-03-27 23:15 5689

Noul Co. Ltd - The RIGHT Foundation Commences Research and Development for Supporting Malaria Control

* Aim to accelerate global business and access to the public market based on reliable research results * Grant funds will be utilized for global clinical studies and cost-effectiveness analysis of the miLab™ Platform over the next three years YONGIN,South Korea, March 27, 2023 /PRNewswire/ --...

2023-03-27 21:00 2494

PharmaBlock Opens New R&D Facility in Pennsylvania -- Expanding Capacity to Deliver GMP Projects

WEST CHESTER, Pa., March 27, 2023 /PRNewswire/ -- PharmaBlock (stock code: 300725.SZSE), a global, fully integrated CDMO company focused on innovative chemistry and low-carbon manufacturing, announces the opening of its new R&D facility inWest Chester, Pennsylvania. The facility expands the comp...

2023-03-27 20:00 2904

BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies

Exclusive Research and Option Agreement With Global Biopharmaceutical Company to Leverage BIORCHESTRA Targeting Technology Platform -BDDS™ - to Develop Nucleic Acid Therapies for Treatment of Neurological Disorders in Multiple Targets CAMBRIDGE, Mass. and DAEJEON, South Korea, March 27, 2023 /PR...

2023-03-27 20:00 2334

YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study

* The trial met its primary endpoint of superior immunogenicity of PIKA COVID-19 Vaccine vs inactivated COVID-19 vaccine, measured by GMT of neutralizing antibody against Omicron virus on Day 14, with statistical significance (95%CI: 2.1, 3.4, P<0.0001) based on interim data analysis * The tr...

2023-03-27 18:00 2507

Noul Co. Ltd - The RIGHT Foundation Commences Research and Development for Supporting Malaria Control

* Aim to accelerate global business and access to the public market based on reliable research results YONGIN, South Korea, March 27, 2023 /PRNewswire/ -- Noul Co. Ltd (CEO :David Lim) announced that it has signed an agreement with The RIGHT Foundation to conduct a global clinical studies to de...

2023-03-27 17:34 2745

Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves

SHANGHAI, March 27, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines inGreater China and other parts of Asia, announced today that it has received full u...

2023-03-27 08:15 4047

Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS

APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency Joenja® is a targeted treatment of APDS for adult and pediatric patients 12 years of age and older Joenja® is expected to launch in the US in early April Pharming will host a con...

2023-03-25 02:51 9576

World TB Day 2023: Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa

Transformative Next Generation Sequencing (NGS) Innovation expands access to genomic testing and enables personalized medicine for patients with Tuberculosis (TB) CAPE TOWN, South Africa, March 24, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-bas...

2023-03-24 16:07 4487

Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results

Company maintains priority focus on clinical programs to develop a novel f unctional cure for hepatitis B viral (HBV) infection and a potential first-of-its-kind treatment for postpartum depression (PPD) and major depressive disorders (MDD) Multiple Phase 2a proof-of-concept (POC) clinical data r...

2023-03-24 13:33 5747
1 ... 248249250251252253254 ... 351